Correction to: Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: A post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial(Journal of Headache and Pain (2018)19:98 DOI: 10.1186/s10194-018-0928-1)

TL;DR: This review provides an update on the epidemiology, pathogenesis, diagnosis, and current treatment of migraine, and summarizes the evidence for fremanezumab as a treatment for migraine.

TL;DR: In this article, the impact of the menstrual cycle on several common neurological conditions, including migraine, seizures, multiple sclerosis, stroke, and Parkinson's disease, was reviewed, and the potential for adverse drug reactions related to menstruation, fertility, and pregnancy outcomes.

TL;DR: In this paper, the authors evaluate the healthcare resource use and cost of lost productivity due to migraine among Italians with ≥4 monthly migraine days (MMDs), with a focus on those with ≥2 prior preventive treatments.

TL;DR: In this article, the authors evaluated the treatment cost and persistence of anti-migraine drugs among migraine patients in Pakistan and found that patients with high frequency (HR, 1.881; 95%CI, 0.762-0.912; p = 0.0002), other comorbidities such as depression, increasing age, and triptan(s) with NSAIDs were at higher risk of treatment discontinuation.